Navigating the Immunogenicity Lifecycle: Strategies for ADA, nAb & Cytokine Profiling
- No Comments
For developers of biologics, cell therapies, and vaccines, "How immunogenic is my drug?" is one of the most critical questions in the development pipeline. An unwanted immune response can compromise safety, alter pharmacokinetics, and neutralize therapeutic efficacy.
Read More